31 The Drug Rediscovery Protocol Table 2. Tumour and biomarker details per patient of the MSI cohort (continued) No. Tumour type Pre-enrolment Baseline WGS CB PFS Somatic or Lynch MSI profile MSI seqa ML JAK1 and/ or JAK2 mutations CD274b COSMIC signaturec 16 CRC Lynch MSH2 mut − SD 36 17 EC Somatic MLH1/PMS2 loss, MLH1 methylation 37.7 798 JAK2 p.Lys1055Glu, JAK2 c.3291 + 8delT 4× 12+, 26+, 6 NE NA 18 EC Somatic MLH1/PMS2 loss, MLH1 methylation − SD >58 19 CRC Somatic MSI, MLH1 not methylated − PR >49 20 CRC Lynch PMS2 mut, MLH1/PMS2 loss, MSI, MLH1 not methylated 57.7 1,048 2× 6+, 15, 1, 9 SD 48 21 CRC Somatic MLH1/PMS2 loss, MLH1 methylation 85.8 1,558 JAK1 p.Lys860fs 2× 6+, 12+, 15, 9 SD 39 22 GBM Lynch PMS2 mut, PMS2 loss, MSS 42.4 6,137 JAK1 p.Gln437His, JAK2 p.Ala586Thr 2× 14+, 1+, 15 PD 13 23 Duodenum Somatic MSH6 loss, MSI 35.6 1,425 JAK2 p.Arg158Gln 2× 6+, 1, 12, 9 PR >63 24 CRC Somatic MLH1/PMS2 loss, BRAFV600E 46.0 1,048 JAK2 c.3291 + 8delT 2× 6, 14, 12 PR >120 25 UCC Lynch MSH6 mut, MSH6 loss 7.2 637 2× 1+, 6+ PD 5 26 Prostate Lynch MSH6 mut − SD >98 27 Prostate Somatic MSI 12.0 543 3× 1+, 6+, 12 PD 15 28 CRC Somatic MLH1/PMS2 loss 60.4 820 2× PD 6 29 CRC Somatic MSH2/MSH6 loss − SD >51 30 EC Somatic MLH1/PMS2 loss 39.3 387 JAK1 p.Pro430fs JAK1 c.2115 + 1G>A 2× 6+, 12+ NE NA 2
RkJQdWJsaXNoZXIy MTk4NDMw